drugset / Trial / NCT03755115
SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
Patients with extensive disease SCLC after failure of first-line treatment were enrolled with SHR-1210 and epirubicin for 3 cycles to evaluate initial efficacy
Timeline
- Start
- 2019-02-01
- Primary completion
- 2019-10-28
- Completion
- 2020-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Epirubicin | Small molecule | 30 mg/m2 | Intravenous |